Barclays’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-78,322
| Closed | -$17.3M | – | 5083 |
|
|
2025
Q4 | $17.3M | Sell |
78,322
-35,057
| -31% | -$5.67M | ﹤0.01% | 1327 |
|
|
2025
Q3 | $10.9M | Buy |
113,379
+83,755
| +283% | +$5.34M | ﹤0.01% | 1606 |
|
|
2025
Q2 | $1.44M | Buy |
29,624
+29,596
| +105,700% | +$711K | ﹤0.01% | 3093 |
|
|
2025
Q1 | $603 | Buy |
+28
| New | +$622 | ﹤0.01% | 5071 |
|
|
2022
Q3 | – | Sell |
-2,209
| Closed | -$22K | – | 4820 |
|
|
2022
Q2 | $22K | Sell |
2,209
-162
| -7% | -$2K | ﹤0.01% | 4352 |
|
|
2022
Q1 | $39K | Hold |
2,371
| – | – | ﹤0.01% | 4209 |
|
|
2021
Q4 | $60K | Sell |
2,371
-246
| -9% | -$7.66K | ﹤0.01% | 3814 |
|
|
2021
Q3 | $117K | Buy |
2,617
+46
| +2% | +$1.75K | ﹤0.01% | 3844 |
|
|
2021
Q2 | $104K | Sell |
2,571
-35
| -1% | -$1.48K | ﹤0.01% | 3830 |
|
|
2021
Q1 | $138K | Buy |
2,606
+2,024
| +348% | +$99.9K | ﹤0.01% | 3871 |
|
|
2020
Q4 | $23K | Sell |
582
-218
| -27% | -$10.8K | ﹤0.01% | 4646 |
|
|
2020
Q3 | $46K | Sell |
800
-115
| -13% | -$8.12K | ﹤0.01% | 4647 |
|
|
2020
Q2 | $68K | Buy |
+915
| New | +$59.3K | ﹤0.01% | 4763 |
|
|
2019
Q4 | – | Sell |
-5
| Closed | – | – | 6374 |
|
|
2019
Q3 | $0 | Buy |
+5
| New | +$168 | ﹤0.01% | 6736 |
|
|
2018
Q2 | – | Sell |
-15
| Closed | -$1K | – | 6988 |
|
|
2018
Q1 | $1K | Sell |
15
-615
| -98% | -$84K | ﹤0.01% | 6944 |
|
|
2017
Q4 | $86K | Buy |
630
+160
| +34% | +$24.3K | ﹤0.01% | 5357 |
|
|
2017
Q3 | $76K | Sell |
470
-575
| -55% | -$81.8K | ﹤0.01% | 5111 |
|
|
2017
Q2 | $157K | Buy |
1,045
+1,042
| +34,733% | +$144K | ﹤0.01% | 4568 |
|
|
2017
Q1 | $0 | Buy |
+3
| New | +$527 | ﹤0.01% | 6768 |
|
|
2016
Q4 | – | Sell |
-5
| Closed | -$1K | – | 6614 |
|
|
2016
Q3 | $1K | Buy |
+5
| New | +$1.16K | ﹤0.01% | 6370 |
|
|
2015
Q4 | – | Sell |
-1
| Closed | – | – | 6026 |
|
|
2015
Q3 | $0 | Sell |
1
-4
| -80% | -$1.14K | ﹤0.01% | 6843 |
|
|
2015
Q2 | $1K | Buy |
+5
| New | +$1.54K | ﹤0.01% | 6905 |
|
Barclays's CDTX Position: Q1 2026 in Review
Barclays sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 78,322 shares — an estimated $17.3M sold.
Barclays first reported a position in CDTX in Q2 2015 and held it in 22 quarters. The position peaked at $17.3M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Barclays reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Barclays sold 78,322 Cidara Therapeutics shares in Q1 2026, an estimated $17.3M.
- Barclays first reported a position in Cidara Therapeutics in Q2 2015 and held it in 22 quarters.
- Barclays's Cidara Therapeutics position peaked at $17.3M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.